November 27, 2017
Two recently filed lawsuits from Allergan PLC are teeing up a pivotal test of the extent to which drug compounders can mass-produce virtual copies of brand-name prescription drugs, attorneys say.
November 15, 2017
A California federal judge on Tuesday kept alive Allergan's false advertising suit against a large drug compounder, saying there are sufficient allegations the compounder is manufacturing eye medicines without adhering to federal law.
October 25, 2017
Allergan has asked a California federal judge not to toss its suit alleging Imprimis Pharmaceuticals illegally manufactures and sells unapproved new drugs under a drug compounding loophole in FDA regulations, saying it has shown that it complies with the Federal Food, Drug and Cosmetics Act and state regulations.